Restricted accessResearch articleFirst published online 2020-8
Associations Between Obesity and the Effectiveness of Anti–Tumor Necrosis Factor-α Agents in Inflammatory Bowel Disease Patients: A Literature Review and Meta-analysis
Background: A total of 15% to 40% of adult inflammatory bowel disease (IBD) patients are obese. The influence of obesity on anti-tumor necrosis factor-α (anti-TNF-α) treatment in IBD patients is not consistent. Objective: To determine the association between obesity and the efficacy of anti-TNF treatment in IBD patients. Methods: We performed a systematic search from January 1990 through November 2019 on MEDLINE, Web of Science, Google Scholar, ClinicalTrials.gov, and Cochrane library. We included randomized controlled trials and observational cohort studies that investigated the outcome of anti-TNF treatment in IBD patients with stratification according to body mass index or body weight. The odds ratio (OR) and its 95% CI were calculated. Results: In this pooled meta-analysis, we observed that obesity increased the odds of failure of anti-TNF therapy (OR = 1.195; 95% CI = 1.034-1.380; P = 0.015; I2 = 47.8%). After performing subgroup analyses, obesity was associated with higher odds of anti-TNF treatment failure in ulcerative colitis (UC) patients (OR = 1.413; 95% CI = 1.008-1.980; P = 0.045; I2 = 20.0%) but not in Crohn’s disease patients (OR = 1.099; 95% CI = 0.928-1.300). Obesity significantly increased the odds of treatment failure of both dose-fixed and weight-based anti-TNF agents (OR = 1.121, 95% CI = 1.027-1.224, P = 0.011, and OR = 1.449, 95% CI = 1.006-2.087, P = 0.046, respectively). Conclusion and Relevance: In our meta-analysis, obesity was associated with the inferior response of anti-TNF treatments in UC patients. Clinicians should be aware that obese UC patients may require higher doses in anti-TNF treatment.
HalesCMFryarCDCarrollMDFreedmanDSOgdenCL.Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007-2008 to 2015-2016. JAMA. 2018;319:1723-1725. doi:10.1001/jama.2018.3060
2.
JensenCBAngquistLHMendallMASorensenTIABakerJLJessT.Childhood body mass index and risk of inflammatory bowel disease in adulthood: a population-based cohort study. Am J Gastroenterol. 2018;113:694-701. doi:10.1038/s41395-018-0031-x
3.
SinghSDulaiPSZarrinparARamamoorthySSandbornWJ.Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017;14:110-121. doi:10.1038/nrgastro.2016.181
4.
NguyenNHOhno-MachadoLSandbornWJSinghS.Obesity is independently associated with higher annual burden and costs of hospitalization in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:709-718.e7. doi:10.1016/j.cgh.2018.07.004
5.
PringlePLStewartKOPeloquinJM, et al. Body mass index, genetic susceptibility, and risk of complications among individuals with Crohn’s disease. Inflamm Bowel Dis. 2015;21:2304-2310. doi:10.1097/MIB.0000000000000498
6.
Stabroth-AkilDLeifeldLPfutzerRMorgensternJKruisW.The effect of body weight on the severity and clinical course of ulcerative colitis. Int J Colorectal Dis. 2015;30:237-242. doi:10.1007/s00384-014-2051-3
7.
SinghSFacciorussoASinghAG, et al. Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS One. 2018;13:e0195123. doi:10.1371/journal.pone.0195123
8.
BultmanEde HaarCvan Liere-BaronA, et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients. Aliment Pharmacol Ther. 2012;35:335-341. doi:10.1111/j.1365-2036.2011.04946.x
KhanSAyyagariRShahRHerreraHSwaroopP.Obesity is linked to higher rates of arthritis and failure to biologics in IBD patients. Am J Gastroenterol. 2012;107:S685-S686.
11.
RosenMHScherlEJSchneiderY, et al. Sa1880 Increased body mass index predicts need for surgery in Crohn’s disease patients treated with certolizumab. Gastroenterology. 2012;142(5):S-348.
12.
HorstSAbou-IshmailAGreenM, et al. Efficacy of and factors contributing to dose adjustment in treatment with certolizumab for Crohn’s disease. Am J Gastroenterol. 2012;107:S680-S681.
13.
HarperJWSinananMNZismanTL.Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2118-2124. doi:10.1097/MIB.0b013e31829cf401
14.
BillietTCleynenIBalletV, et al. Prognostic factors for long-term infliximab treatment in Crohn’s disease patients: a 20-year single centre experience. Aliment Pharmacol Ther. 2016;44:673-683. doi:10.1111/apt.13754
15.
GuerbauLGerardRDuveauN, et al. Patients with Crohn’s disease with high body mass index present more frequent and rapid loss of response to infliximab. Inflamm Bowel Dis. 2017;23:1853-1859. doi:10.1097/MIB.0000000000001179
16.
KurnoolSNguyenNHProudfootJ, et al. High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis. Aliment Pharmacol Ther. 2018;47:1472-1479. doi:10.1111/apt.14665
17.
QumseyaBNaikASAnanthakrishnanAN, et al. Increased BMI is not associated with dose escalation or failure of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009;136(5, suppl 1):A-655.
18.
MooreJMBeaulieuDBHorstSN, et al. Adalimumab and certolizumab pegol for the treatment of Crohn’s disease: does BMI make a difference?Gastroenterology. 2011;140(5, suppl 1):S-588.
19.
ClickBTuskeyAGBehmBW.Sa 1925 Does obesity impact treatment efficacy of adalimumab and certolizumab pegol in Crohn’s disease?Gastroenterology. 2012;142(5, suppl 1):S-361.
20.
BrownPClarkTDowsonG, et al. Relationship of body mass index to clinical outcomes after infliximab therapy in patients with Crohn’s disease. J Crohns Colitis. 2016;10:1144-1150. doi:10.1093/ecco-jcc/jjw079
21.
MadsenKGPottegardAHallasJKjeldsenJ.Treatment failure of TNF-α inhibitors in obese patients with inflammatory bowel disease—a cohort study. Inflamm Bowel Dis. 2018;24:2628-2633. doi:10.1093/ibd/izy178
22.
HigginsJPTSterneJACSavovićJ, et al. A revised tool for assessing risk of bias in randomized trials. Cochrane Database Syst Rev. 2016;10(suppl 1):29-31.
23.
StangA.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603-605. doi:10.1007/s10654-010-9491-z
24.
ScaldaferriFD’AmbrosioDHolleranG, et al. Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with infliximab. PLoS One. 2017;12:e0186575. doi:10.1371/journal.pone.0186575
25.
DingNSMalietzisGLungPFC, et al. The body composition profile is associated with response to anti-TNF therapy in Crohn’s disease and may offer an alternative dosing paradigm. Aliment Pharmacol Ther. 2017;46:883-891. doi:10.1111/apt.14293
26.
SandbornWJRutgeertsPFeaganBG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250-1260. doi:10.1053/j.gastro.2009.06.061
27.
ColombelJFSandbornWJReinischW, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383-1395. doi:10.1056/NEJMoa0904492
28.
ReinischWSandbornWJHommesDW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780-787. doi:10.1136/gut.2010.221127
29.
SandbornWJSchreiberSFeaganBG, et al. Certolizumab pegol for active Crohn’s disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011;9:670-678.e3. doi:10.1016/j.cgh.2011.04.031
30.
SandbornWJvan AsscheGReinischW, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-265.e1-e3. doi:10.1053/j.gastro.2011.10.032
31.
KobayashiTSuzukiYMotoyaS, et al. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis. J Gastroenterol. 2016;51:241-251. doi:10.1007/s00535-015-1102-z
32.
BondAAsherRJacksonR, et al. Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels. Eur J Gastroenterol Hepatol. 2016;28:271-276. doi:10.1097/meg.0000000000000544
33.
ParkHSParkJYYuR.Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes Res Clin Pract. 2005;69:29-35. doi:10.1016/j.diabres.2004.11.007
34.
HotamisligilGSArnerPCaroJFAtkinsonRLSpiegelmanBM.Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95:2409-2415. doi:10.1172/JCI117936
35.
DotanIRonYYanaiH, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014;20:2247-2259. doi:10.1097/MIB.0000000000000212
36.
TabriziMATsengCMRoskosLK.Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11:81-88. doi:10.1016/S1359-6446(05)03638-X
37.
SteenholdtCBendtzenKBrynskovJAinsworthMA.Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. Inflamm Bowel Dis. 2016;22:1999-2015. doi:10.1097/MIB.0000000000000772
38.
SinghSHeienHCSangaralinghamLR, et al. Comparative effectiveness and safety of anti-tumor necrosis factor agents in biologic-naive patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2016;14:1120-1129.e6. doi:10.1016/j.cgh.2016.03.038
39.
WangRDasguptaAWardMM.Comparative efficacy of tumor necrosis factor-alpha inhibitors in ankylosing spondylitis: a systematic review and Bayesian network metaanalysis. J Rheumatol. 2018;45:481-490. doi:10.3899/jrheum.170224
40.
AnanthakrishnanANCaganACaiT, et al. Comparative effectiveness of infliximab and adalimumab in Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2016;22:880-885. doi:10.1097/MIB.0000000000000754
41.
StidhamRWLeeTCHigginsPD, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;39:1349-1362. doi:10.1111/apt.12749
42.
BakounyZYaredFEl RassyE, et al. Comparative efficacy of anti-TNF therapies for the prevention of postoperative recurrence of Crohn’s disease: a systematic review and network meta-analysis of prospective trials. J Clin Gastroenterol. 2019;53:409-417. doi:10.1097/MCG.0000000000001006
43.
SeminerioJLKoutroubakisIERamos-RiversC, et al. Impact of obesity on the management and clinical course of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:2857-2863. doi:10.1097/MIB.0000000000000560
44.
CrohnBBGinzburgLOppenheimerGD.Regional ileitis; a pathologic and clinical entity. Am J Med. 1952;13:583-590.
LightnerALTseCSPotterDDJrMoirC.Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease. J Pediatr Surg. 2018;53:1706-1709. doi:10.1016/j.jpedsurg.2017.09.019
47.
CaneteFManosaMClosACabreEDomenechE.Review article: the relationship between obesity, bariatric surgery, and inflammatory bowel disease. Aliment Pharmacol Ther. 2018;48:807-816. doi:10.1111/apt.14956
48.
LichtensteinGRFeaganBGCohenRD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012;107:1409-1422. doi:10.1038/ajg.2012.218
49.
HanauerSBFeaganBGLichtensteinGR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549. doi:10.1016/S0140-6736(02)08512-4
50.
PresentDHRutgeertsPTarganS, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398-1405. doi:10.1056/NEJM199905063401804
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
